Un ensayo de 68 semanas publicado en el Revista de Medicina de Nueva Inglaterra mostraron que los participantes que tomaron semaglutida perdieron un promedio de 14% de su peso corporal, en comparacin con una prdida del 3% en el grupo placebo
Quick Facts & Key Specifications This section identifies the product, package configuration, catalogue metadata, molecular identity, and analytical-document set
Nature 595 , 309314 (2021)
PMID: 15 ZengKLiWWangYZhangZZhangLZhangWet al
During this period, many patients begin to notice a decrease in appetite and a reduced desire for large meals
Key findings include: Despite sharing the same active ingredient as Ozempic, Wegovy (higher-dose semaglutide) has been linked to: This has led to a surge in lawsuits against Wegovy